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Abstract
Background: The emergence of different viral infections during the last decades like dengue, West Nile, SARS,
chikungunya, MERS-CoV, Ebola, Zika and Yellow Fever raised some questions on quickness and reliability of
laboratory diagnostic tests for verification of suspected cases. Since sampling of blood requires medically
trained personal and comprises some risks for the patient as well as for the health care personal, the sampling by non-
invasive methods (e.g. saliva and/ or urine) might be a very valuable alternative for investigating a diseased patient.
Main body: To analyse the usefulness of alternative noninvasive samples for the diagnosis of emerging infectious viral
diseases, a literature search was performed on PubMed for alternative sampling for these viral infections. In total, 711
papers of potential relevance were found, of which we have included 128 in this review.
Conclusions: Considering the experience using non-invasive sampling for the diagnostic of emerging viral diseases, it
seems important to perform an investigation using alternative samples for routine diagnostics. Moreover, during an
outbreak situation, evaluation of appropriate sampling and further processing for laboratory analysis on various
diagnostic platforms are very crucial. This will help to achieve optimal diagnostic results for a good and reliable
case identification.
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Background
The emergence of several virus infections during the last
decades like dengue, West Nile (WN), Severe acute re-
spiratory syndrome (SARS), chikungunya (CHIK), Mid-
dle East respiratory syndrome coronavirus (MERS-CoV),
Ebola (EBO), Zika (ZIK) and Yellow Fever (YF) raised
some questions on quickness and reliability of laboratory
diagnostic tests for verification of suspected cases. All
important questions arising with an emerging infection
like source and route of transmission, infectivity of pa-
tients, recommendation of safety measures for health
care personal and distribution in an animal reservoir or
other vectors require the performance of laboratory
diagnosis. To investigate the patient’s infections most
often a blood sample is taken not only for the analysis of
blood parameters but also for pathogen detection mostly
by PCR or for testing the presence of specific antibodies.
However, sampling of blood requires medically trained
personal and comprises some risks for the patient as
well as for the health care personal. In particular the
blood sampling of patients with highly infectious haem-
orrhagic fever like Ebola involve a great risk for the
physician and the patient. Therefore, the sampling by
non-invasive methods (e.g. saliva and/ or urine) might
be a very valuable alternative for investigating a diseased
patient. The use of saliva and urine for the diagnosis for
many viral infections has been reported, however, it is
often not performed in the broad routine diagnostics.
After a viral infection it usually takes some days until
the propagation of the virus causes symptoms and a
clinical investigation of a patient is indicated. Blood sam-
pling for analysing blood parameters belongs to a rou-
tine procedure in developed countries. This is different
in developing countries, where extensive analyses of
clinical parameters are not performed routinely due to
financial and technical constraints. Even though the
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sampling of swaps from the respiratory tracks is a com-
mon procedure for influenza, SARS, MERS-CoV and
other respiratory infections, the sampling of blood is the
prevalent procedure for all other recently emerged vi-
ruses. However, with the introduction of the highly sen-
sitive Nucleic Acid Tests (NAT) for diagnostic also
additional samples like saliva and/or urine were included
in diagnostic sample collections. The advantage of using
non-invasive samples like saliva for dengue serology was
successfully proven 18 years ago by Cuzzubbo et al. who
discovered that dengue primary and secondary infections
can be distinguished by the level of IgG in saliva [1].
The specificity of the diagnosis of acute flavivirus infec-
tions like dengue, WN and YF has been improved by ap-
plying the NAT because it is not impeded by the
widespread cross-reactivity found for most serological
assays [2]. Since urine, saliva and other non-invasive
samples were not part of the routine investigation, the
sampling procedures and the samples containment are
also very different. These differences complicate the in-
terpretation of diagnostic findings and therefore an
optimization for these samplings is required. An im-
provement of the sampling and stabilization of viral
RNA in the diagnostic material will help to increase sig-
nificantly the diagnostic sensitivity.
To analyse the usefulness of alternative non-invasive
samples for diagnostic of infectious viral diseases like
SARS, WN, dengue, MERS-CoV, Ebola, Zika and YF, we
reviewed the importance of saliva and urine for the diag-
nosis of recently emerging viruses in comparison to con-
ventional blood sampling. Since the extensive evaluation
of different samples for human patients is often not per-
formed, also investigations of animal models or vectors
are considered. Therefore, we performed an electronic
literature review on PubMed for alternative sampling for
SARS, WN, dengue, MERS-CoV, Ebola, Zika and YF.
Main text
Method of literature search
A review of the literature for urine and saliva samples
for diagnostic of CHIK, dengue, Ebola, WN, Zika, YF,
SARS and MERS was performed using the electronic
database PubMed. The period for searches was 1st
January 1980 – 26th August 2016.
Appropriate articles were selected according to their
abstracts and further reviewed for reason for diagnostic
analysis, sample types used and the methods applied for
diagnosis focusing on saliva and urine as test samples.
Search profile used for this review in PubMed for
CHIK as an example:
"chikungunya virus"[MeSH Terms] OR ("chikungu-
nya"[All Fields] AND "virus"[All Fields]) OR "chikun-
gunya virus"[All Fields] AND ("saliva"[MeSH Terms] OR
"saliva"[All Fields])
"chikungunya virus"[MeSH Terms] OR ("chikungu-
nya"[All Fields] AND "virus"[All Fields]) OR "chikun-
gunya virus"[All Fields] AND ("urine"[Subheading] OR
"urine"[All Fields] OR "urine"[MeSH Terms])
Another 42 references were considered for analysing
the preparation and storage of diagnostic samples as
demonstrated in Table 1, see Additional file 1 for de-
tailed methodology.
The literature research revealed 711 papers, of which
we considered 128 in this study (Additional file 1: Figure
S1). Furthermore 43 publication analysing the sample
processing and preparation were included.
Our analysis shows that there should be put more em-
phasis on non-invasive sampling to disclose more easy
alternatives for collecting human samples for clinical
and routine investigations. The present review provides
some indications that non-invasive sampling offers a
promising alternative for routine diagnostic as well as a
favourable diagnostic approach for surveillance studies
with high numbers of samples. The review provides an
overview of the usability of non-invasive sample for
diagnostics of emerging viruses and tries to give recom-
mendation on how this experience could be helpful for
future possible outbreaks of emerging viruses.
Chikungunya
After an epidemic at La Reunion in 2005, an autochthone
outbreak in Italy in 2007 and, spread in Caribbean islands
in December 2013, chikungunya (CHIK) emerged in 2014
for the first time in Central America spreading into South
America and North America [3–7]. Typical clinical speci-
mens for CHIKV are blood, serum and plasma, but also
urine, saliva and in rare cases CSF (Table 1, Additional file
1: Table S1). A systematic evaluation of the CHIK infec-
tion in mice and Cynomolgus macaques revealed the in-
fectivity of different body fluids like saliva, urine and
vaginal swaps [8]. This could be confirmed by analysis of
saliva samples from 4 out of 13 acute CHIKV patients
with haemorrhagic manifestations, which were found to
contain viral RNA and infectious virus. Another study
shows that RNA of chikungunya virus can be detected in
the saliva at the first seven days of infection but with a
lower efficacy than blood samples [9]. Also the detec-
tion of CHIKV genome by RT-PCR in urine was suc-
cessful in one returning traveller, which is a valuable
confirmation of the positive serology [10]. Based on
the experience with other viral infections, the analysis
of throat swabs and urine are part of recommenda-
tion for CHIK diagnostic [11].
Dengue
Common clinical specimens used for dengue infection
are blood, plasma and serum, but also in some cases
CSF and breast milk (Table 1, Additional file 1: Table
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S2). Interestingly, the twenty-two selected publications
described very well the progress of using saliva and urine
as non- invasive samples. Based on the existing IgG
ELISA for serology, they found that the IgG levels in sal-
iva could be applied to differentiate between dengue pri-
mary and secondary infection [1]. One year later,
Artimos de Oliveira et al., used saliva for detection of
specific IgM of recent infections [12]. In 2000 Torres et
al., found for the first time evidence of DENV RNA in
saliva and plasma by RT-PCR [13]. The evaluation of sal-
iva samples as alternative approaches for serological
diagnosis (IgM, IgG, IgA) was further investigated and
complemented by more systematic kinetics analysis of
1st and 2nd infections also comprising urine as an add-
itional alternative sample [14, 15]. Since the sensitivity
(93.3%), specificity (100%), positive predictive value
(100%), and negative predictive value (83.3%) of the de-
tection of IgG in saliva are high, it was considered as
promising sample type for dengue diagnostics [16]. Also
in case reports analysing acute infections, the detection
of DENV in urine and saliva by RT-PCR as well as the
application of filter-paper for saliva sampling prove the
usefulness of these non-invasive samples [17–19]. The
utility of saliva in an assay that detects DENV-specific
IgA in the early phase of a 2nd dengue infection shows
100% sensitivity from day-one after fever onset with a
good correlation to IgA levels in serum and 97% specifi-
city [20]. DEN NS1 antigen was detected in urine in
around two third of dengue fever and DEN haemor-
rhagic fever (HF) using ELISA. Follow up the excretion
of NS1 in urine is very important particularly in patients
developing DF or DHF as an indication of protein leak-
age. The study demonstrates that the NS1 strip assay is
less sensitive for urine compared to the ELISA and both
assays need further adaptation to improve the sensitivity
[21]. This was confirmed by a later study from Saito et
al. showing that urine samples could be used for NS1
antigen ELISA but only in case of serum samples are
very limited or in poor resource settings [22].
From 2012, more studies were performed using saliva
and urine samples besides serum for quantitative RT-PCR
and other parameters (NS1, IgM, IgG) for dengue diag-
nostic during the course of the disease [23–25]. Further
studies underline the benefit of saliva as a diagnostic tool
for use in developing tropical countries like India never-
theless further research is encouraged before implementa-
tion [26]. The delayed release of DENV in urine allows the
diagnosis of an acute dengue infection by RT-PCR and se-
quencing on day 8 and 18, while the respective serum
samples collected on the same period were negative for
DENV [27].
All these promising results using urine and saliva sam-
ples for diagnostics stimulated further investigations on
DENV RNA stability in urine and serum as well as es-
tablishing novel diagnostic device (stacking flow plat-
form) for single-step detection of a target antibody in
salivary fluid [28, 29]. Both studies investigated different
conditions using urine or saliva samples for the diagnos-
tics. One study focused on the storage conditions for
these samples while the other improved the sample pro-
cessing to optimize diagnostics using saliva. Andries et
al. performed a representative study by analysing plasma,
saliva and urine in 267 patients by applying various mo-
lecular and serological analyses. Unfortunately, the per-
formances of these assays were better upon using
plasma samples [30]. Analysing commercial rapid diag-
nostic tests (RDT) for detection of NS1/IgG/IgA in urine
and saliva samples suggested that these RDT kits are of
higher specificity and limited sensitivity [31]. Interest-
ingly, in dengue secondary infection, the IgA in urine at
4-7 days of disease onset is higher than those with 1st in-
fections indicating severe Dengue [32]. Therefore, DENV
IgA in urine is an indicator for the disease severity and
must be investigated.
Ebola and other viral hemorrhagic fevers (VHFs)
Ebola virus and other viral hemorrhagic fevers are
mostly detected in blood derived samples such as whole
blood, plasma or serum. Recent studies reported Ebola
detection also in body fluids including saliva, urine,
sweat, tears, semen and vaginal discharge as well as
feces, ammonitic fluids, placenta and breast milk (Table
Table 1 Overview of selected publications describing samples used for viral diagnostic
Type of specimens Arboviruses VHFV Coronaviruses
CHIKV DENV WNV YFV ZIKV EBOV SARS MERS
Blood derived samples whole blood [139] [143] [147, 148] n.r. [88] [160] [165] [170]
peripheral blood (cells) [139] [144] [147, 148] n.r. n.r. [54] [166]
peripheral blood (plasma) [140] [13] [149] [152] [89] [54] [112, 166]
seruma [141] [144] [149] [152] [97] [52] [167] [169]
umbilical cord blood n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r.
Body fluids saliva [19] [13] n.r. ? [88, 89, 97] [52] n.r. n.r.
urine [19] [19] [75] [104] [88, 89, 97] [54] [110, 112] [124]
VHF Viral haemorrhagic Fever, a = NAT & Immunological test, n.r. not reported
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1 and Additional file 1: Table S3).The search for alterna-
tive sampling for Ebola yielded 34 publications from
which 11 were performed during the recent Ebola out-
break from 2015/2016. Other publication were found for
other VHF viruses like Hanta, 9 hits; Marburg, 4; Junin,
3; VHFs in general 2; Lassa, 2; Crimean Congo
hemorrhagic fever (CCHF), 2; Rift Valley fever (RVF), 1;
Guanarito, 1 and 1 for a novel Bunya virus.The first re-
port dated from 1980 for RVF virus detection in saliva
based on experimentally infected sheep and showed suc-
cessful virus isolation from saliva [33]. This was com-
pleted by the extensive analysis of infected rodents as
main transmission vectors for Hantavirus [34]. Besides
virus excretion, Hanta virus could be demonstrated in
several organs (lung, kidney, salivary glands and liver) by
virus isolation from saliva, urine and feces for up to one
year post inoculation. Also the intensive investigation of
an imported Lassa case to the UK demonstrated the
high viral load in blood taken eleven days post onset of
the disease as well as significant virus count in urine on
day 36, while throat swabs did not yield any detectable
virus [35]. These findings were confirmed during the in-
tensive analysis of an acute Lassa virus infected patient
when the use of urine as additional sample to serum was
successfully investigated for viral RNA by PCR [36].
Vereta and colleagues used urine and urine sediment
epithelium for the identification of acute Hanta virus pa-
tients showing hemorrhagic fever with renal syndrome
(HFRS) [37, 38]. Urine becomes an important sample for
serological studies since antibody excretion in the urine
coincided with the period of renal structure damage and
stopped when the normal renal function was restored.
The first successful Hantavirus isolation of a fatal HFRS
case used urine and brain tissue and was further con-
firmed by RT-PCR [39]. Henceforward, urine was used
for antigen and genome detection as well as for serology
in experimentally infected pigs demonstrating that pigs
can be the host for the viral transmission of HFRS virus
[40]. Petterson et al. could demonstrate that hantavirus
RNA was found in saliva few days after disease onset
[41]. The association between the anti-Hantavirus IgA
and Hantavirus RNA in saliva was inverse, the same is
true for detecting RNA and antigen in endothelial cells
within the parotid gland of HFRS patients [42]. In a re-
cent study, the anti-Hantavirus antibodies in saliva was
detected in a risk group in farms in Yorkshire, UK [43].
Hereby, the non-invasive saliva sampling confirms the
usefulness of Hantavirus surveillance studies for analyz-
ing the presence of Hantavirus in previously unknown
risk areas. Also a recent investigation of Hanta virus per-
sistence in wild rodents is based on the analysis of viral
RNA in saliva, urine and feces show a peak during the
first month after seroconversion continuing throughout
the 8 month study [44].
Urine and saliva as non-invasive samples were also
successfully used for analyzing the pathogenesis of Junin
virus in the rodent vector responsible for virus transmis-
sion for up to 480 days post infection [45, 46]. Surviving
animals showed a viral dissemination in brain, spleen,
kidney and salivary glands with half of the animals shed-
ding Junin virus and the other half being negative for in-
fectious virus, while seroconverted. These findings were
successfully used for analyzing the prevalence of Junin
virus in the rodent population in endemic areas defining
risk areas for the Junin virus infection [47].
Non-invasive samples like urine were used for the ana-
lysis of guinea pig and Rhesus macaques infectivity ex-
periments with highly infectious and deadly Marburg
virus [48]. In particular for dangerous biosafety level 4
pathogens the sampling of blood is very risky and la-
boratory infections are possible, which can be avoided
by sampling urine. In the guinea pig model, the persist-
ent shedding of Marburg virus in saliva, urine and feces
showed that as early as by the end of incubation period
and throughout the disease, the virus could be found in
the feces and saliva virtually in the same concentrations
[49], while in the blood the content of the virus was high
and increased by the end of the disease. A similar ap-
proach was used investigating bat fecal and urine sam-
ples for Marburg virus after infection of a tourist visiting
a cave in Uganda [50]. Around 2.5% of liver/spleen tis-
sues of captured bats were positive in RT-PCR for Mar-
burg virus. Moreover, the virus was detected in 15
different tissues and plasma of Egyptian fruit bats sub-
cutaneously inoculated with Marburg virus, while lim-
ited results were obtained applying mucosal swab
samples, urine and fecal samples [51].
Antibodies against Ebola virus could not be found in
oral fluids, while 100% agreement between the presence
of RNA in serum and oral fluids by RT-PCR was ob-
served [52]. Moreover, in 26 confirmed Ebola cases, 16
samples including saliva, stool, semen, breast milk, tears,
nasal blood and a skin swab were positive in Ebola cul-
ture and/or RT-PCR [53]. In case of EBOV, all samples
including body fluids must be handled applying the
WHO recommendations, since they are highly infec-
tious.The recent Ebolavirus outbreak in Serra Leone,
Liberia und Guinea with 11,325 deaths initiated several
intensive investigations of different patient specimens
like blood, urine, sweat, saliva, conjunctival swaps, stool
and semen for infectious virus [54, 55]. These became a
major interest since transmission routes were not always
obvious from previous experience. Moreover, public
health measures require clear references, when recov-
ered patients are not infectious anymore and can be re-
leased from quarantine. The excretion of EBOV in body
fluids from infected or recovered patients create a great
risk for person in contact [54, 56] as the Ebola virus
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RNA was detected in the following body fluids weeks up
to several months after infection: saliva, conjunctiva/
tears, stool, vaginal fluid, sweat, urine, amniotic fluid,
aqueous humor, cerebrospinal fluid, breast milk, and
semen raised many concerns regarding the long term
transmissibility of infectious virus causing a recrudesce
of an outbreak [56–58]. Comparing whole-blood with
urine specimen’s analysis from Ebola patients in a novel
diagnostic film-array with RT-PCR shows a reasonable
match of 90% for whole blood and 85% for urine [59].
Testing the stability of Ebola virus RNA in human blood
and urine under environmental African conditions
shows that viral RNA testing from blood samples stored
in EDTA buffer is more sensitive [60]. Viral RNA in
urine seems less stable compared to blood since urine
samples were found positive by RT-PCR by day 10-14
compared to blood until at least day-18. Since the CCHF
outbreak in Turkey in 2002, the detection of virus in
other body fluids received attention to avoid secondary
infections. RNA of CCHF virus was identified in the sal-
iva and the urine of 5/6 and 2/3 patients, respectively
[61]. This was confirmed by a later study, which de-
tected CCHF virus in urine samples of patients with pro-
longed viremia [62].
Furthermore, nasopharyngeal aspirates and/or urine
were considered as diagnostic samples evaluating a
multiplex hybridization array for detecting various infec-
tious diseases [63]. Interestingly, the Plasmodium falcip-
arum was identified as a cause of death in a case of
hemorrhagic fever like illness during the Marburg
hemorrhagic fever outbreak in Angola in 2004-2005.
Also a novel diagnostic array based on beads technology
for detection of multiple bat-borne viruses including
Ebola and Nipha viruses used urine from wild bats from
Australia and Bangladesh for a surveillance study [64].
Analyzing cases in China of a hemorrhagic fever due
to a novel Bunya virus, the RNA was identifed in the
blood as well as in urine, throat, and fecal specimens
[65]. Further studies are necessary to investigate the sig-
nificance of non-invasive samples for analyzing the virus
pathogenesis and the infectivity of different body fluids.
West Nile
Clinical specimens used for WNV detection are blood
derived samples and CSF (Table 1 and Additional file 1:
Table S4). Since the safety of blood banks was import-
ant, testing of blood samples was the evident choice.
Even though Steele et al. found infectious WN in several
organs (brain, heart, spleen, liver, kidney, adrenal intes-
tines, pancreas, lung and ovary) of birds, it took four
years until Tesh and others published the investigation
of urine samples used for pathogenesis studies in ham-
sters and birds [66–69]. These findings were later con-
firmed in different animal models like chipmunks, fox
squirrels, hamsters and mice analyzed for WNV patho-
genesis research [70–74]. The first report of WN detec-
tion in urine was in an acute severe case with
encephalitis found positive eight days after symptoms
onset [75]. Further studies detected WNV RNA up to
6.7 years in urine indicating for a persistent renal infec-
tion for several years [76]. This was confirmed by a
number of studies demonstrating the long persistence of
WNV particularly in patients with WN fever compared
to patients with WN neuro-invasive disease, which had a
higher vireamia for a shorter period than those with
West Nile fever [77–80]. In the meantime, the advantage
of using urine instead or additionally to serum is dem-
onstrated by many investigations and could prove its
value also for routine diagnostic [81–86]. Also WNV
could be successfully isolated from urine samples and
further analyzed by sequencing.
In summary, one could state that the use of urine is a
suitable alternative diagnostic sample compared to
serum and should be listed in fact sheets from national
and international organizations (WHO, PAHO, CDC,
ECDC). Further studies are needed investigating if urine
samples are a useful source for surveillance studies for
WNV distribution and for analyzing the severity of the
disease in patients with neuro-invasive and/or kidney
manifestation.
Zika
The Zika virus was detected in blood, serum, saliva, and
urine, as well as in semen, vaginal discharge, sweat,
tears, ammonitic fluids, placenta and breast milk (Table
1 and Additional file 1: Table S5). The expansion of Zika
to Brazil via New Caledonia 2015 stimulates the devel-
opment of diagnostic assays for NAT and serology to
analyze the increasing number of cases [87]. In a surveil-
lance study, ZIKV was identified in 19.2% (total 182 pa-
tients) of saliva samples, but not in blood [88]. The
detection of ZIKV in saliva samples increased the mo-
lecular detection rate of ZIKV in acute case but ZIKV
did not persist for longer time frame in saliva as in urine
or semen. Nevertheless, saliva sample was advantageous
in children and neonates [89]. Interestingly, the ZIKV
can be detected in urine samples for even longer. Com-
bination of urine and saliva besides serum is of great
significant in ZIKV diagnostics [90]. This was also true
in a rhesus macaque model used for analyzing plasma,
saliva, urine and cerebrospinal fluid by RT-PCR for
ZIKV detection [91].
Moreover, RNA of ZIKV was detected in semen by
RT-PCR on the 7th day of the appearance of symptoms
but was not identified on the 21st day, which was con-
firmed by Reusken et al. [92, 93]. This finding conse-
quently leads to the possibility of an infection via sexual
intercourse as documented by D'Ortenzio et al. with a
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high viral load in the semen obtained on sample col-
lected after 18 days [94, 95]. In several smaller and big-
ger studies, the usability of saliva and urine beside blood
samples was demonstrated for the Zika virus diagnostics
[96–98]. The excretion of viral RNA in urine and saliva
was observed for up to 29 days after symptom onset and
with higher viral load than in blood [99, 100]. The high
risk for transmission by patient’s body fluids also raised
concern for appropriate safety measures for health care
personal as discussed in several publications [101–103].
Yellow Fever
Yellow Fever is generally detected in blood, plasma,
serum and CSF as other flaviviruses (Table 1 and Add-
itional file 1: Table S6). Although alternative samples
demonstrate their usefulness for other flavivirus infec-
tions like urine or saliva samples for diagnostics of den-
gue or West Nile, YF were not investigated until 2011
[104, 105]. These are the first reports showing the use-
fulness of urine samples for diagnostic of adverse events
after YF vaccination. For vaccinees developing severe
side effects after vaccination it could be clearly shown
that viral shedding is prolonged up to day 25 post vac-
cination. The release of YF RNA could be found in urine
at day 198 after vaccination. If the detection of the YF
attenuated 17D vaccine virus could be demonstrated in
urine easily. However, representative data of alternative
samples like urine or saliva from YF infections are miss-
ing. In particular for cases with a severe course of dis-
ease with numerous hemorrhagic bleedings the use of
non-invasive sampling would be a real alternative pre-
venting bodily injury of the patient.
Severe acute respiratory syndrome (SARS)
When SARS emerged in November 2002, it was obvious
to analyze samples from the respiratory tract for diag-
nostic. However, even for the first SARS patients other
samples beside blood and nasopharyngeal aspirate sam-
ples like feces and urine were found positive with 97%
and 42% for viral RNA, respectively [106] (Table 1 and
Additional file 1: Table S7). This was confirmed by ana-
lysis of throat wash and saliva showing a high virus load
up to 6x106 and 6x108 RNA copies per ml, respectively
[107]. Moreover, the detection of SARS in plasma, spu-
tum, endotracheal aspirates, stool, throat swabs and sal-
iva revealed significant differences between the types of
samples [108] as all samples from the lower respiratory
tract were tested positive. Cheng et al. found that death
was associated with higher virus load in nasopharyngeal
specimens obtained on day 10 after the onset of symp-
toms [109]. Different samples like serum, nasopharyn-
geal aspirates (NPA), throat swabs, nasal swabs, rectal
swab, stool and urine were used for analysis of the viral
pathogenesis during the course of the disease [109–112].
The diarrhea and hepatic dysfunction was associated
high viral load in NPA, while in urine is associated with
abnormal urinalysis findings. The extensive analysis of
415 SARS patients revealed the presence of SARS in
respiratory specimens two weeks after disease onset,
and in stool, rectal swab and urine specimens for up
to four weeks. Throat and nasal swabs is less signifi-
cant that the NPA specimens, therefore, the high viral
load in NPA has a major impact on the airborne
transmission, which played a major role during the
outbreak in Hong Kong [113].
The evaluations of commercial PCR kits and
in-house antigen-ELISAs for the quality of SARS diag-
nostic are an important task to select the most appro-
priate test for the selected sample. The sensitivity of
RT-PCR is higher compared to two antigen-ELISAs
[114] as RNA of SARS-CoV can be detected earlier in
fecal specimens in around 80% of patients and in 25%
of urine samples. Based on all these findings, RT-PCR
is the method of choice for early diagnosis of SARS
CoV infection [115, 116].
The co-presence of viral RNA and antibodies in
plasma was observed over three weeks in two cases
[117]. In addition, the SARS-CoV was isolated from
stool or urine specimens for longer than 4 weeks [118].
Since the detection of SARS virus is possible in various
clinical samples (NPA, throat-swab, fecal, cerebrospinal
fluid, blood and urine) by viral culture or RT-PCR clear
and significant recommendations for diagnostic of SARS
based on the previous experiments worked out by the
WHO and the Multi-Centre Collaborative Network re-
quire an appropriate update. Even though SARS did not
appear any more after the outbreak except for the two
laboratory infections thereafter [119–171].
Bats are the most likely animal vector for CoVs [121].
Also experiments in mice and rhesus macaque analyzing
the viral pathogenesis for the development of effective
strategies for diagnosis, prevention, therapy and vaccine
design was further evaluated [122, 123]. Since salivary
gland epithelial cells were affected as a first target after
infection the immunization with virus like particles
might be eliciting a protective immune response against
SARS-CoV generating a mucosal immunity. This new
vaccine approach provides important information for fu-
ture vaccine design.
Middle East respiratory syndrome coronavirus (MERS-
CoV)
A boost of nearly 50 publications on alternative sampling
within three years demonstrates the importance and docu-
ments the public health concern with this respiratory dis-
ease caused by a new Corona virus (CoV) (Additional file
1: Table S8). The publications can be roughly categorized
as follows 11 case reports, 7 descriptions of pathogenesis,
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11 on recommendation and investigation of diagnostics, 7
on recommendation and analysis of risks for health care
workers, 2 recommendations for patient management and
5 on control and prevention including treatment and vac-
cine development. Only a few selected publications were
considered for this review. Bronchoalveolar and lower re-
spiratory tract fluids were highly positive for MERS-CoV
in the two identified cases [124], while urine samples were
only positive on day 13. Stool samples and oro-nasal
swabs contained very low MERS-CoV copy number on
days 12 and 16, respectively, and no virus was detected in
blood. In the beginning of the outbreak the way of trans-
mission was rather unclear. Therefore, the virus replica-
tion in the kidney with potential shedding in urine was
further investigated [125]. To clarify the different trans-
mission routes a prediction model for oral-fecal and/or
oral-saliva transmission routes for MERS-CoV was devel-
oped and evaluated [126]. Very soon camels as contribut-
ing animal host for MERS-CoV infection got into focus of
investigation and it became obvious that also dromedary
camels in Eastern Africa and the Arabian Peninsula have a
very high seroprevalence of MERS-CoV antibodies [127].
For further surveillance studies in camels, hedgehogs, and
bats very often non-invasive samples like urine, saliva,
fecal nasal swaps, fecal swaps or camel milk were used to
analyze for MERS-CoV RNA or specific antibodies [128].
In summer 2015, 183 confirmed cases of MERS and 33 fa-
talities were reported in the Republic of Korea caused by a
nosocomial outbreak [129].
The timing and intensity of respiratory viral shedding
in MERS-CoV infected patients is still of major interest
as airborne transmission from human to human by
droplets seems to be the dominant infection route [130–
132]. It might be that the introduction of the isothermal
amplification (LAMP or RPA) for detecting of emerging
diseases provides a useful tool for quick and reliable
diagnostic of acute cases and might lead to an immedi-
ate public health response including the appropriate
safety precautions for the medical personal [133, 134].
Based on the experience with other respiratory infec-
tions and based on the lessons learned from the previous
SARS outbreak the analysis of respiratory samples are
parts of the routine samples taken for diagnostic of sus-
pected MERS patients.
Conclusions
The analysis of using other non-invasive samples for
virus diagnostics clearly shows that the procedures for
the optimal sampling strategy of the different viral infec-
tions are not seriously investigated table S9. In the fol-
lowing overview it became obvious that for the newly
emerging viruses like CHIK, MersCoV and Zika more
and broader attempts for sampling strategies were
performed and investigated than for well known viruses
like YF and dengue.
The application of saliva as a sample of choice for the
diagnosis of CHIK fever infections in small children or
patients whose blood samples are difficult to obtain is of
great significant. However, all recommendations/fact
sheets for CHIK from national and international organi-
zations (CDC, PAHO, WHO, ECDC) do not mention
saliva or urine samples as suitable material for diagnosis
because of the missing of meaningful studies that evalu-
ate saliva and urine as diagnostic samples compared with
blood. Hopefully, there will be studies performed an-
swering these questions with a representative number of
CHIK patients in the future.
The use of saliva and urine for the diagnosis of acute
dengue infections is of great importance and requires
more attention. Present studies show the usefulness for
these samples for diagnostics and also the monitoring of
the severity of infection. In particular for surveillance
studies and/or investigation of small children the nonin-
vasive approach using saliva or urine for the laboratory
diagnosis of dengue cases should be considered when
blood samples are difficult to obtain. Although the appli-
cation of alternative samples for the diagnostic became
more popular in the recent years, further studies and
improvements are necessary to establish these samples
equally to common plasma or serum samples. Com-
mercial assays as well as appropriate sampling equip-
ment have to be verified for diagnostic applicability in
representative cohorts and during the course of the
disease. It seems that the increased awareness of al-
ternative samples stimulates such studies for dengue
diagnosis as demonstrated in the recent publications
mentioned above.
In particular for diagnostic of VHF cases, the investiga-
tion of the usefulness of non-invasive taken samples
should have high priority since blood sampling from such
patients is highly risky and often dangerous for patients
with hemorrhagic symptoms while continuous bleeding
occurs. The virus load in sever cases of VHF is very high
in body fluid and the NAT is the method of choice since
the production of specific IgM and/or IgG antibodies
takes a few days. In very severe cases, the patient even can
pass away before developing a detectable antibody reac-
tion, while a general viremia affecting several organs and
is detectable in most body fluids. In less severe cases, the
exact moment becomes an important issue since viremia
only remains for just a few days (3-4 days) and often pa-
tient samples were taken too late for successful NAT thus
requiring laborious serology testing with in-house assays
and risk of false positive reactivity. Onset of disease is also
not a well-defined point of time because the perception of
a disease might be different in developing compared to de-
veloped countries. This makes the comparison of clinical
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symptoms and diagnostic findings during the course of
the disease even more difficult.
Although the analysis of different body fluids during the
recent Ebola virus outbreak expands our knowledge of
virus transmissibility via eye fluid and semen tremen-
dously, systematic studies on which and for how long the
different body fluids will contain viral RNA and/or infec-
tious viruses are still missing. Recommendations on how
non-invasive sampling should be performed, what kind of
samples are necessary and how they should be stabilized
and transported under African environmental conditions
are still missing and require thoroughly investigations.
For WNV infections the use of urine is a suitable al-
ternative diagnostic sample compared to serum and
should be listed in fact sheets from national and inter-
national organizations. Further studies are needed inves-
tigating if urine samples are a useful source for
surveillance studies on WNV distribution and for ana-
lyzing the severity of the disease in patients with
neuro-invasive and/or kidney manifestation. The emer-
gence of Zika virus tremendously stimulated the investi-
gation of using non-invasive samples as saliva and urine
for diagnostic of Zika virus infections. From the start of
the Zika outbreak in French Polynesia saliva was consid-
ered as alternative material for the diagnostics. The in-
vestigation of urine and saliva shows a higher virus load
compared to blood making these samples a suitable al-
ternative to blood. However, this information has to be
forwarded to the physicians as it is already part of the
PAHO and WHO recommendations.
For YF diagnostic one can hope that the integration of
saliva and urine as alternative samples into the recom-
mendation worked out by the WHO for the recent out-
break will help to implement this method into the
medical procedure and create some meaningful results
for future outbreak scenarios.
Even although SARS seems to have disappeared from
the globe, the experience and findings on which and
when the different diagnostic samples should be used
for a quick and reliable diagnostic should be carefully
evaluated, since respiratory infections are on the rise as
we have seen a few years later by the influenza and
MERS-CoV outbreaks. The great variety on which, how
and when respiratory samples have to be taken is
reflected by the list of nomenclature found in the publi-
cations: for upper respiratory specimens (nasal swab,
exudate nose, oronasal swab, pharyngeal swab, tracheal
swab, exudate mouth, saliva and sputum) and lower re-
spiratory specimens (bronchoalveolar fluid, bronchoal-
veolar lavage). Recommendations for standardized
procedures for sampling and handling of the respiratory
samples will help to allow a better comparison of the
findings and provide a better preparedness for the next
respiratory disease outbreak.
Because of a higher virus load, samples from the lower
respiratory tract are more suitable for diagnostic. How-
ever, the sampling of bronchoalveolar-lavage fluid is also
invasive and requires an experienced physician and
holds a certain risk of nosocomial infections by aerosols.
Other non-invasive samples like urine, nasal, pharyngeal,
tracheal and rectal swabs were included in the diagnostic
analysis for analyzing the pathogenesis and the kinetic of
virus release by the different body fluids. Like for SARS
standardized procedures for sampling and handling of
the respiratory samples will help to allow a better com-
parison of the findings and provide a better prepared-
ness for future respiratory disease outbreak.
The present review clearly shows that there is still the
need to perform more diligent studies analyzing non-in-
vasive patient samples in comparison with blood and
serum samples, which used for routine diagnostic of
emerging viral diseases. While for some diseases like the
respiratory infections, the sampling of nasal swaps and
saliva is part of routine sampling, for other viral infec-
tions, blood or serum seems the predominant and only
type of sample used for laboratory diagnosis.
This is in particular disappointing because non-inva-
sive sampling offers a real alternative avoiding additional
risk for the patient and the medical personal. Patients
suspected to be infected by VHF usually have a very high
virus load. Therefore, the analysis of saliva or urine
should be routinely performed in parallel to investigation
of blood samples. Based on a solid database it will be
possible to determine the most appropriate sample for a
viral diagnosis before it gets implemented in the routine
diagnostic procedure. Diagnostic laboratories and physi-
cians have to gain knowledge when and how alternative
samples have to be considered for analyzing an acute or
convalescent viral infection. Even though, we have with
NAT a very sensitive diagnostic tool, the best point in
time during the course of the disease together with the
optimal sampling, sample storage and sample prepar-
ation are essential to get optimal results for a laboratory
diagnosis. In patients presenting with a moderate or
mild disease, the viremia is mostly very short lasting just
1-3 days. For these patients the positive NAT is some-
times difficult to achieve and a negative finding is of no
predictive value since the virus titer might be just below
the detection limit or sample storage and sample prep-
aration is not optimal in case of non-invasive sampling
such as saliva and urine. Although the virus disap-
peared from the blood, the virus genome will be still
detectable in the urine as consequence of the clearance
process as we have found in Yellow Fever vaccinees or
other for Zika [97, 104]. In contrast, we find a high viral
load in patients developing a severe disease sometimes
with a general infection affecting several organs. In par-
ticular in those patients, the detection of the
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pathogenic virus by NAT is not difficult analyzing dif-
ferent types of samples. Very often the viral load also
reflects the severity of the disease and can be used as
prognostic marker for progression of the disease in the
patient. Exactly for these patients the non-invasive sam-
pling is less stressful as frequent bleeding performed
with the current procedure. This becomes even more
important, if point of care diagnostic allows a more fre-
quent monitoring of infection parameters of the dis-
eased patient in the future. For the recently emerging
CHIK and Zika in South America, the analysis of throat
swaps, saliva and urine samples were already analyzed
for their usability in diagnostics. However, the findings
are based on case studies or small studies and require a
more systematic approach. Preferably there should be
performed a systematic analysis of different invasive
samples (blood, bronchoalveolar lavage) and
non-invasive samples (saliva, urine, etc.) for their diag-
nostic value using different diagnostic methods for pa-
tients with acute and convalescent disease when new
infections emerge. This also implies that the procedure
taking samples has to be somehow standardized. This
became very obvious by the large number of terms for
upper and lower respiratory samples most likely reflect-
ing the great variety how the samples were taken. This
makes the comparability of diagnostic findings pre-
sented in different studies very difficult. To address this
problem a clear recommendation for the sampling pro-
cedure would help to overcome this imponderability.
Furthermore, the methods for storage of the samples
regarding temperature and stabilization needs to be
worked out to allow an optimal transport and prepar-
ation of the diagnostic sample. For example there are
special sampling tubes with stabilizer available for both
saliva (DNAgard Saliva by biomatrica, USA) and urine
(VACUETTE Urine CCM tubes by Greiner Bio-One,
Germany and Urine Monovette by Sarstedt, Germany),
which will help preserves the integrity of sample at room
temperature. Sample preparation from urine and saliva
could be also challenging especially for molecular diagnos-
tics, therefore it is very important to optimize protocols
using clinical samples rather than spiked mock-samples.
Our personal experience showed that the optimized sam-
ple preparation method on real clinical samples was not
as efficient as on spiked mock samples.
The increasing number of publications considering al-
ternative sampling for diagnostic of the recent outbreaks
MERS-CoV, CHIK, Ebola and Zika are promising. How-
ever, systematic studies are rare and for some infectious
disease outbreaks like the recent yellow fever in Angola,
non-invasive samples for diagnostic are still uncommon
and require further investigation. Just for diseases like
yellow fever, non-invasive samples like urine or saliva
might be a very practical alternative, since the first index
patients are detected often very late, while blood will be
negative by NAT in patients with mild disease and from
patients with a severe disease it is difficult taking blood
because of a hemorrhage clinical picture. Non-invasive
samples might be also a great alternative for investiga-
tions of children or other patients were collection of
blood samples is difficult [18, 30, 88]. Also for large
surveillance studies, non-invasive samples like saliva
and/or urine could be performed without medical per-
sonal for collecting blood. However, the usability of
these samples for serology or NAT has to be evaluated
in comparison to conventional use of sera. Therefore, it
is necessary to introduce non-invasive sampling strat-
egies in recommendations as done for the “Yellow
Fever Laboratory Diagnostic Algorithm” worked out for
the epidemic and non-epidemic countries in Africa dur-
ing the YF outbreak in Angola by WHO expert team
[135]. Since these investigations could be only per-
formed during an outbreak situation the preparation of
a scheme for evaluation of sampling for respiratory as
well as for other infectious diseases including the fur-
ther processing for laboratory diagnostic is highly rec-
ommended. This more structured approach will help to
improve the diagnostic of emerging infectious diseases
significantly as new diagnostic methods and platforms
are developed continuously and require effective evalu-
ation under real conditions.
For confirmation of a clinical diagnosis a correct la-
boratory diagnosis is essential for all further steps of
patient's treatment and handling. In particular for
new and/or emerging diseases, the conditions for the
best sampling regarding time and source (blood,
serum, saliva, urine, etc.) are often not known. Since
every disease has its own course of symptoms and af-
fected organs, the optimal sampling schema might
change and require different strategies regarding sam-
ple preparation and processing. While in the early
phase when disease symptoms appear often the viral
pathogen could be detected by nucleic acid testing in
blood or other body fluids in the later phase only
antibodies are detectable in serum.
In the present article, we analyzed over 700 scientific
publications on diagnostic approaches for dengue, West
Nile, SARS, chikungunya, MERS-CoV, Ebola, Zika and
Yellow Fever regarding their relevance for using alterna-
tive samples like saliva and urine for their versatility for
virus diagnostic. The use of non-invasive samples offers
a suitable alternative for improving the diagnostic per-
formance and significantly reduces the risk for medical
personal and patients for routine diagnostic and during
an outbreak situation. The advantage of using non-inva-
sive samples for the diagnostic has to be seriously ana-
lyzed and investigated before implementing in the
routine diagnostics.
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